Testing vancomycin for newly diagnosed multiple sclerosis
Treatments studied
Part of Brain & nervous system, Immune system & allergy clinical trials.
This Phase 1 study tests whether the antibiotic vancomycin can be given safely to people with newly diagnosed multiple sclerosis (or related early stages). It mainly focuses on safety and side effects, and whether the approach is feasible for this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 to 50
- Your MS is newly diagnosed (or you have CIS/RIS) and symptoms started within the last year
- You have not started MS treatments yet
- You have not taken antibiotics in the last 90 days
- You can have MRIs safely (no certain metal implants) and you have no vancomycin allergy or major kidney/ear problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral drug called VT7208 in both healthy volunteers and people with multiple sclerosis (MS). The goal is to see if it is safe and how the body processes it, which could lead to a new treatment option for MS.
This study tests whether adding a probiotic supplement to your usual MS treatment (or to no treatment) can help manage relapsing-remitting multiple sclerosis. It aims to see if the probiotic is safe and beneficial as an add-on therapy.
This early phase trial tests a new treatment called GC012F for people with multiple sclerosis. It aims to see how safe and tolerable it is, and may offer a new option for those whose current treatments are not working well enough.
This study tests a new treatment that combines a type of immune cell therapy with a targeted antibody to see if it can help people with multiple sclerosis. It aims to reduce the immune system's attack on the nervous system and potentially slow disease progression.
This study tests a new treatment called SYS6020 for people with multiple sclerosis (MS) that has not improved with standard therapies. The treatment aims to reduce MS activity and disability progression.
This trial compares two ways of dosing vancomycin (an antibiotic) for serious MRSA infections by using different blood test targets. The goal is to see if the newer approach works at least as well as the standard one, while keeping patients safe.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.